|
A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma. |
|
|
No Relationships to Disclose |
|
|
Employment - Caris Life Sciences; Indivumed |
|
Honoraria - AstraZeneca/MedImmune; Bayer/Onyx; Caris Life Sciences; Daiichi Sankyo/Lilly; Merck; Pfizer; Seagan; Taiho Pharmaceutical |
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Genentech/Roche; Merck; Pfizer; Seagen; Taiho Pharmaceutical |
Speakers' Bureau - Caris Life Sciences; Merck; Pfizer; Seagan; Taiho Pharmaceutical |
Research Funding - Genentech; Natera |
|
|
Consulting or Advisory Role - RenovoRx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Apple (I) |
Honoraria - Rafael Pharmaceuticals |
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; HalioDx; Merus NV |
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Seagen; Sirtex Medical; Taiho Pharmaceutical |
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst) |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences; Merus NV |
|
|
Research Funding - Genentech (Inst); Natera (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Erytech Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Erytech Pharma |
|
|
Consulting or Advisory Role - Celgene; Ipsen; Taiho Pharmaceutical |
Speakers' Bureau - Celgene; Daiichi Sankyo/Astra Zeneca; Taiho Pharmaceutical |
Research Funding - ERYTECH Pharma |